Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals's GHG Emissions Data Preview
In 2024, Cosmo Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Cosmo Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy/Paste is a PRO feature.  a | 0000000 | Copy/Paste is a PRO feature. | 0000000 |
Total Scope 3 | Copy/Paste is a PRO feature. | Copy/Paste is a PRO feature. | 0000000 | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0000000 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature. | 0000000 |
Verified Sources Behind Cosmo Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Cosmo Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Insights into Cosmo Pharmaceuticals's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Cosmo Pharmaceuticals amounted to 5,714.27 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Cosmo Pharmaceuticals increased by 7.23%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
Cosmo Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Cosmo Pharmaceuticals's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Cosmo Pharmaceuticals were 5,657.69 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2023), Cosmo Pharmaceuticals's Scope 1 emissions increased by 7.24%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
What are Cosmo Pharmaceuticals's Scope 2 emissions?
In 2024, Cosmo Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 56.58 tCO₂e without specifying the calculation method.a
Has Cosmo Pharmaceuticals reduced its Scope 2 emissions over time?
Compared to the previous year (2023), Cosmo Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Cosmo Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
What methodology does Cosmo Pharmaceuticals use for Scope 2 reporting?
In 2024, Cosmo Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.a
Cosmo Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Cosmo Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Cosmo Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 5,657.69 tCO₂e and total revenues of USD 260 millions. This translates into an emissions intensity of 21.74 tCO₂e per millions USD.a
Cosmo Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers
How does Cosmo Pharmaceuticals's GHG emissions intensity compare to its peers?
In 2024, Cosmo Pharmaceuticals reported a Scope 1 emissions intensity of 21.74 tCO₂e per millions USD. Compared to the peer group median of 8.11, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
Where does Cosmo Pharmaceuticals rank on GHG emissions intensity within its industry?
In 2024, Cosmo Pharmaceuticals ranked 19 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Cosmo Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a